Schildkraut JM - Search Results

1

Ovarian cancer risk, ALDH2 polymorphism and alcohol drinking: Asian data from the Ovarian Cancer Association Consortium.

Ugai T, Kelemen LE, Mizuno M, Ong JS, Webb PM, Chenevix-Trench G; Australian Ovarian Cancer Study Group; Wicklund KG, Doherty JA, Rossing MA, Thompson PJ, Wilkens LR, Carney ME, Goodman MT, Schildkraut JM, Berchuck A, Cramer DW, Terry KL, Cai H, Shu XO, Gao YT, Xiang YB, Van Den Berg D, Pike MC, Wu AH, Pearce CL, Matsuo K; Ovarian Cancer Association Consortium. Ugai T, et al. Among authors: schildkraut jm. Cancer Sci. 2018 Feb;109(2):435-445. doi: 10.1111/cas.13470. Epub 2018 Jan 21. Cancer Sci. 2018. PMID: 29247577 Free PMC article.

2

Oral contraceptive pills. Prevention of ovarian cancer and other benefits.

Berchuck A, Schildkraut J. Berchuck A, et al. N C Med J. 1997 Nov-Dec;58(6):404-7; discussion 408. N C Med J. 1997. PMID: 9392951 Review.

3

Effect of BRCA1 and BRCA2 on the association between breast cancer risk and family history.

Claus EB, Schildkraut J, Iversen ES Jr, Berry D, Parmigiani G. Claus EB, et al. J Natl Cancer Inst. 1998 Dec 2;90(23):1824-9. doi: 10.1093/jnci/90.23.1824. J Natl Cancer Inst. 1998. PMID: 9839523

4

Impact of progestin and estrogen potency in oral contraceptives on ovarian cancer risk.

Schildkraut JM, Calingaert B, Marchbanks PA, Moorman PG, Rodriguez GC. Schildkraut JM, et al. J Natl Cancer Inst. 2002 Jan 2;94(1):32-8. doi: 10.1093/jnci/94.1.32. J Natl Cancer Inst. 2002. PMID: 11773280

5

Ovulation and ovarian cancer: a comparison of two methods for calculating lifetime ovulatory cycles (United States).

Moorman PG, Schildkraut JM, Calingaert B, Halabi S, Vine MF, Berchuck A. Moorman PG, et al. Among authors: schildkraut jm. Cancer Causes Control. 2002 Nov;13(9):807-11. doi: 10.1023/a:1020678100977. Cancer Causes Control. 2002. PMID: 12462545

6

High expression of tumor necrosis factor-related apoptosis-inducing ligand is associated with favorable ovarian cancer survival.

Lancaster JM, Sayer R, Blanchette C, Calingaert B, Whitaker R, Schildkraut J, Marks J, Berchuck A. Lancaster JM, et al. Among authors: schildkraut j. Clin Cancer Res. 2003 Feb;9(2):762-6. Clin Cancer Res. 2003. PMID: 12576447

7

No relationship between ovarian cancer risk and progesterone receptor gene polymorphism in a population-based, case-control study in North Carolina.

Lancaster JM, Wenham RM, Halabi S, Calingaert B, Marks JR, Moorman PG, Bentley RC, Berchuck A, Schildkraut JM. Lancaster JM, et al. Among authors: schildkraut jm. Cancer Epidemiol Biomarkers Prev. 2003 Mar;12(3):226-7. Cancer Epidemiol Biomarkers Prev. 2003. PMID: 12646513 No abstract available.

8

Characterization of prediagnostic symptoms among primary epithelial ovarian cancer cases and controls.

Vine MF, Calingaert B, Berchuck A, Schildkraut JM. Vine MF, et al. Among authors: schildkraut jm. Gynecol Oncol. 2003 Jul;90(1):75-82. doi: 10.1016/s0090-8258(03)00175-6. Gynecol Oncol. 2003. PMID: 12821345

9

Matrix metalloproteinase-1 gene promoter polymorphism and risk of ovarian cancer.

Wenham RM, Calingaert B, Ali S, McClean K, Whitaker R, Bentley R, Lancaster JM, Schildkraut J, Marks J, Berchuck A. Wenham RM, et al. Among authors: schildkraut j. J Soc Gynecol Investig. 2003 Sep;10(6):381-7. doi: 10.1016/s1071-5576(03)00141-2. J Soc Gynecol Investig. 2003. PMID: 12969782

10

Polymorphisms in BRCA1 and BRCA2 and risk of epithelial ovarian cancer.

Wenham RM, Schildkraut JM, McLean K, Calingaert B, Bentley RC, Marks J, Berchuck A. Wenham RM, et al. Among authors: schildkraut jm. Clin Cancer Res. 2003 Oct 1;9(12):4396-403. Clin Cancer Res. 2003. PMID: 14555511

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

372 results

Search Page